Glycoproteomics Landscape of Asymptomatic and Symptomatic Human Alzheimer's Disease Brain

• Type of Material: Article
• Authors: Suttipong Suttapitugsakul, Harvard Medical School; Kathrin Stavenhagen, Harvard Medical School; Sofia Donskaya, Harvard Medical School; David A Bennett, Rush University; Robert G Mealer, Harvard Medical School; Nicholas Seyfried, Emory University; Richard Cummings, Emory University
• Language: English
• Date: 2022-12-01
• Publisher: ELSEVIER
• Publication Version: Final Published Version
• Copyright Statement: © 2022 The Authors
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.mcpro.2022.100433
• Title of Journal or Parent Work: MOLECULAR & CELLULAR PROTEOMICS
• Volume: 21
• Issue: 12
• Start Page: 100433
• End Page: 100433
• Grant/Funding Information: This work was supported by the National Institute of Health grant RF1AG062181 to R. D. C., RF1AG057471 to N. T. S., RF1AG057470 to N. T. S., and R01AG061800 to N. T. S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
• Keywords: Biochemistry & Molecular Biology; GLYCOME; ACID; Science & Technology; AFFINITY-CHROMATOGRAPHY; Life Sciences & Biomedicine; SERUM; EXPRESSION; Biochemical Research Methods; GLYCOSYLATION; PROTEIN-TAU
• Research Categories: Health Sciences, Medicine and Surgery; Chemistry, Biochemistry

Abstract

Molecular changes in the brain of individuals afflicted with Alzheimer's disease (AD) are an intense area of study. Little is known about the role of protein abundance and posttranslational modifications in AD progression and treatment, in particular large-scale intact N-linked glycoproteomics analysis. To elucidate the N-glycoproteome landscape, we developed an approach based on multi-lectin affinity enrichment, hydrophilic interaction chromatography, and LC-MS–based glycoproteomics. We analyzed brain tissue from 10 persons with no cognitive impairment or AD, 10 with asymptomatic AD, and 10 with symptomatic AD, detecting over 300 glycoproteins and 1900 glycoforms across the samples. The majority of glycoproteins have N-glycans that are high-mannosidic or complex chains that are fucosylated and bisected. The Man5 N-glycan was found to occur most frequently at >20% of the total glycoforms. Unlike the glycoproteomes of other tissues, sialylation is a minor feature of the brain N-glycoproteome, occurring at <9% among the glycoforms. We observed AD-associated differences in the number of antennae, frequency of fucosylation, bisection, and other monosaccharides at individual glycosylation sites among samples from our three groups. Further analysis revealed glycosylation differences in subcellular compartments across disease stage, including glycoproteins in the lysosome frequently modified with paucimannosidic glycans. These results illustrate the N-glycoproteomics landscape across the spectrum of AD clinical and pathologic severity and will facilitate a deeper understanding of progression and treatment development.